Market Access Manager- Oncology

Join EVA Pharma, a leading pharmaceutical company dedicated to empowering the fight for Health and well-being as a fundamental human right. Recognized and certified as a best place to work, we are committed to fostering a supportive and innovative environment for our team members.

Job Summary

• We are seeking a strategic and passionate Market Access Manager – Oncology to join our team.
• This role is central to ensuring that EVA Pharma’s oncology portfolio achieves optimal patient access and reimbursement.
• The successful candidate will design and execute market access strategies, engage with stakeholders, and champion the value of our therapies across diverse healthcare systems.

Key Responsibilities

• Develop and implement tailored market access strategies for EVA Pharma’s oncology products.
• Lead the preparation of value dossiers, HTA submissions, and reimbursement negotiations.
• Collaborate with cross-functional teams (Medical Affairs, Regulatory, Commercial, Governmental Affairs) to align access strategies.
• Build and maintain strong relationships with payers, policy makers, healthcare providers, and patient advocacy groups.
• Monitor healthcare policy, oncology reimbursement trends, and competitive dynamics to anticipate challenges and opportunities.
• Support evidence generation initiatives, including real-world data and HEOR studies, to strengthen product value propositions.
• Track and report on market access performance metrics to drive continuous improvement.

Requirements

• Bachelor’s degree in pharmacy, or related field (master’s degree is preferred).
• Minimum 2 years of experience in market access or health economics, within the pharmaceutical industry.
• Strong knowledge of healthcare systems, reimbursement processes, and payer dynamics in Egypt.
• Excellent communication, negotiation, and stakeholder management skills.
• Proven ability to manage complex projects and work cross-functionally.
• Oncology experience is highly desirable.
• Experience engaging with HTA bodies and developing value dossiers.